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Preventionofrestenosisaftersuccessfulpercu= 
taneous tranduminal coronary balloon angio- 
plasty (PEA) continues to present thegreatest 
therapeutkt chalienge in interventional cardiol- 
o$y. Experimental and pat-l studies de. 
scribe mstenosls as no more than the biologic 
healing respome to arterial Injury. Studies of se. 
rial quantitative coronary angiography have dem- 
onstrated that th& biologic process may be mea- 
sured as the loss in minimal luminal diameter 
(MID) from post-PTCA to follow-up anglography 
and that it Is essentially ubmltous and normally 
distributed. Thus, quantitative coronary angiogra- 
phy has become the gold standard for evaluation 
of the a-graphic outcome of clin~l trials of 
new agents and devices aimed at prevention of 
restenosis. The 3-hydroxy.3.methylglutaryl-coen- 
zyme A (HMOCoA) reductase inhibitors inhibit 
MosynUmb of mevakmate, a precursor of non- 
sterol compounds hwolved in cell prolbration, 
and thus may control the neointlmal response, 
which forms the kernel of restenosis. Experimen- 
tal evidence suggests that fluvastatin may exert 
a greater direct Inhibitory effect on proliferating 
vascular myocytes than other HMO-CoA reduc- 
tase inhlbttors, independent of any Iipkl-mng 
action.ThePknfastatinAngioplastyRestenosis 
(FLARE) Tdal was conceived, in collaboration be. 
tween the Thoraxcenter, Erasmus Unhrersity, Rot- 
terdam, me Netherlands, and Sandoz Pharma, to 
evaluate the ability of fluvastatin 40 mg twsce 
dally to reduce restenods after successful 
From the Thoraxcenter, Erasmus University, Rotterdam (D.P.F., 
P.W.S.), Catharina Hospital, Eindhoven (H.B.), The Netherlands; 
Guy’s Hospital, London, England (G.J.); University Hospital San 
Carlos, Madrid, Spain (CM.); Royal Infirmary, Glasgow, Scotland 
(J.S.); and St. Jans Hospital, Genk, Belgium (MV). 
Address for reprints: Patrick W. Serruys, MD, PhD, Erasmus 
University Ee 2332, P.O. Box 1738, 3000 DR Rotterdam, The 
Netherlands. 
singie-lesion PTCA. Treatment of suitable pa- 
tients beglns 2 weeks before P7CA and continues 
after successful PTCA (residual diameter steno. 
sis <Joe/o, without major cardiac complications) 
to folk~up angiography at 26 f 2 weeks. Reste. 
nosisis measured by quantiie coronary angi- 
ography at a core laboratory as the loss in MID 
from post-PTCA to follow-up angiography. tt is 
cakulated (so% power, (Y = 0.05) that 730 evalu- 
able patients will be needed to test the hypoth- 
esis that fluvastatin will reduce the expected 
post-PTCA loss in MLD by 40%. Serial lipkl analy- 
sis will be carried out at a central laboratory. Trial 
evaluation is focused on the primary endpoint 
(change in MID) but includes primary clinical end- 
points (death, myocardial infarction, or the need 
for coronary artety bypass graft surgery or rein- 
tervention up to 40 weeks after PTCA) as well as 
secondary and tertiary clinical, angiographic, and 
laboratory endpohW According to this methodo- 
w approach, the effect of fluvastatin on lumi- 
nal renamng and clinical events after success. 
fd PTCA as well as possible assodations of lipid 
parameters with restenosis can be comprehen- 
siveiy hlvestiied. 
(Am J Cardid 1994373:5OD-SlD) 
esion recurrence, or restenosis, remains the L bane of percutaneous transluminal coro- nary angioplasty (PTCA) in the treatment 
of obstructive coronary artery disease.’ Much has 
been written on the pathobiologic nature of reste- 
nosis as well as conceptual, intellectual, and meth- 
odologic approaches to its study, elaboration, and 
discussion in the clinical field. The fundamental 
pathogenesis of restenosis appears to mimic, for 
the most part, the biologic tissue-healing response 
to injury.2,3 A brief and general summary of the 
mechanisms and time course begins with the obliga- 
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tory intimal disruption caused by effective coronary vention, evaluation of the effectiveness of therapy, 
angioplasty, in response to which there is immedi- using clinical parameters, is subjective and thus 
ate platelet aggregation and adhesion, with conse- prone to considerable imprecision.t5 Similarly, the 
quent release of a plethora of intracellular sub- use of noninvasive tests of myocardial perfusion or 
stances, including growth factors.2j49 Many growth function has been reported to be unreliable for this 
factors have been identified as participating in the specific purpose. r5-t7 Therefore, because coronary 
process that culminates in neointimal hyperpla- angiography has been (and is still) the only univer- 
sia,” but the complete picture of their complex sally available coronary artery imaging technique, 
interaction, at cellular and subcellular levels in most clinical studies investigating restenosis have 
viva, remains to be clarified, although rapid and become angiographically oriented. This situation 
extensive Progress is being made. Suffice it to say 
that the end result of the cascade of reactions 
has been enhanced by the advent of sophisticated, 
initiated by vessel wall trauma is the conversion of 
objective, and reproducible quantitative coronary 
the CjUieSCellt COIltEXtile smooth lllUSCk Cell t0 it!3 
angiography analysis systems for measurement of 
synthetic proliferative phenotype.+lO According to 
coronary lumina] dimensions.18 Thus, traditional 
the conventional understanding of the process,2 
visual assessment of the angiogram has been super- 
this activation is initiated in the media,” but within 
seded,19 and increasing application of quantitative 
the first few days, migration takes place into the 
coronary angiography has considerably advanced 
disrupted intima, where endothelial cells are also 
understanding of the general process of restenosis 
proliferating in an attempt to restore an intact 
after interventions. Further, the physiologic rel- 
luminal surface. 
evance of luminal measurements provided by reli- 
Within the first few days after trauma, the 
able quantitative assessment systems has now been 
synthetic smooth muscle cells already begin to 
well described.20,21 The most important contribu- 
produce abundant proteoglycan” (a bulky, extracel- 
tions of quantitative coronary angiography have 
lular matrix substance). By 2 weeks after injury, 
emerged from detailed study of large patient groups 
some of the synthetic smooth muscle cells already 
undergoing serial coronary angiography before and 
begin to readopt a quiescent, contractile appear- 
after intervention and at predesignated 6-month 
ance,“J2 and this pattern progresses at a rate that 
follow-up, in the context of multicenter clinical 
depends on a number of factors, particularly the 
trials or large single-center experience. Luminal 
extent of injury, and parallels the gradual replace- 
renarrowing after intervention is now universally 
ment of proteoglycan in the extracellular matrix by 
perceived as a normally distributed phenomenon 
collagen during the succeeding months.12J3 
that affects treated lesions to variable degrees,22J3 
Throughout this period, the now characteristic 
can be angiographically detected as early as 1 
histologic appearance of intimal hyperplasia may 
month after intervention, and tends to peak at 
be observed, i.e., proliferating smooth muscle cells 
about 6 months, with minimal further progression 
in varying concentrations, against a background of 
after that.24,25 As already described, such a time 
a loose, mainly proteoglycan, matrix.12J3 By 6 
course has been demonstrated in experimental 
months, basal conditions of the preinjury vessel 
models of tissue injury and arterial injury in particu- 
wall tend to have been restored, with intact endo- 
lar, allowing the interpretative conclusion that the 
thelial layer and predominance of contractile 
angiographic perception of restenosis as a normally 
smooth muscle cells, now in a mainly collagenous 
distributed process of luminal renarrowing or 
matrix.14 Few human postmortem studies have 
10~s~~~~~ is well in keeping with the paradigm of a 
been conducted, and these involve small patient 
biologic phenomenon. The application of categori- 
numbers; however, findings in lesions where PTCA 
cal definitions for the occurrence (or nonoccur- 
had been carried out > 2 years previously appear 
rence) of restenosis, as has been carried out in 
to be histologically indistinguishable from conven- many large trials until recent years, is therefore 
tional atherosclerotic plaque.12 inappropriate and provides an incomplete and 
inaccurate evaluation of the process.2c28 To com- 
pare the effects of alternative treatment options for 
ASSESSMENT OF RESTENOSIS prevention or control of the extent of this tissue 
IN CUNICAI. TRIALS response to injury, a continuous approach to evalu- 
ContrlbutIonofQuantItaUveCoronary~- ation is clearly mandatory, whereby all patients 
raphy: Although improvement in the functional treated in a common manner are considered as a 
and symptomatic status of patients is the ultimate single group.26-29 
therapeutic goal when undertaking coronary inter- As a consequence of the limited knowledge of 
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the specific pathobiologic pathways leading to neo- 
intimal hyperplasia, many different pharmacologic 
interventions, including antiplatelet agents, throm- 
boxane receptor antagonists, serotonin antago- 
nists, calcium antagonists, antimitotic agents, angio- 
tensin-converting enzyme inhibitors, steroids, 
somatostatin analogues, anticoagulants, and fish 
oils have been used in prospective randomized 
trials to prevent restenosis, without conclusive 
success.29-31 Until 1990, most clinical trials aimed 
at restenosis prevention were limited in their 
methodologic approach by 3 major shortcomings: 
(1) insufficient patient population, (2) incomplete 
angiographic follow-up, and (3) diversity in the 
angiographic definition of restenosis.26 Since then, 
a number of large, carefully designed, randomized, 
placebo-controlled trials have been carried out in 
Europe and North America, with quantitative 
coronary angiographic endpoints and high rates of 
complete angiographic follow-up.32-35 However, in 
1994, it may still be confidently stated that to date 
no pharmacologic agent has been convincingly 
demonstrated to reduce or control the degree of 
luminai renarrowing after successful PTCA.31 
Potential role of HMO-CoA reductase inhibi- 
tars In prevention of rest~~osls: The 3-hydroxy- 
3-methylglutaryl-coenzyme A (HMG-CoA) reduc- 
tase inhibitors are the most recently introduced 
class of agents aimed at management of hyperlipid- 
emia. By inhibiting this enzyme, the reduction of 
HMG-CoA to mevalonic acid, the rate-limiting 
step in cholesterol biosynthesis, is prevented.36 The 
result is primarily a reduction in low density 
lipoprotein cholesterol, because the low density 
lipoprotein cholesterol receptor is stimulated by 
depletion of the endogenous cholesterol pool. 
Data from many clinical investigations of these 
compounds have suggested that their beneficial 
effect on progression of atherosclerosis is due to 
their lipid-lowering properties.37,38 Use of these 
compounds has also allowed the appreciation of 
the importance of mevalonate as a precursor of 
isoprenoid groups as well as cholesterol in such 
fundamental biologic processes as cell growth and 
proliferation.39 In addition, mevalonate (or its 
product or products) has recently been shown to be 
necessary for esterification of intracellular choles- 
terol by acetylated low density lipoprotein choles- 
terol in macrophages,40 a process that may lead to 
lipid accumulation in the arterial wall, which is a 
fundamental step in atheroma formation.41 
Of even greater interest for restenosis preven- 
tion is a recent experimental study’* in normocho- 
lesterolemic rabbits, which investigated a possible 
direct effect of 4 HMG-CoA reductase inhibitors 
on smooth muscle cell proliferation after carotid 
artery injury (imparted by surgical placement of a 
hollow external Silastic collar), independent of any 
lipid-lowering action. A direct independent myo- 
cyte inhibitory effect was indeed confirmed, and, 
further, considerable differences were unveiled in 
the degree of inhibition of neointimal formation 
between the 4 compounds evaluated, with fluva- 
statin (Sandoz) demonstrating the greatest effect 
(over simvastatin, lovastatin, and pravastatin, in 
that order). These differences in neointimal inhibi- 
tory effect between the compounds were attributed 
to diversities in relative lipophilicity, thus in tissue 
distribution and also in the relative efficacy of 
inhibition of HMG-CoA reductase. Because the 
inhibitory effects of HMG-CoA reductase inhibi- 
tors on myocyte proliferation have previously been 
prevented by addition of mevalonate to a culture of 
proliferating rat carotid smooth muscle cells, it has 
been concluded that blockade of intracellular meva- 
ionic acid synthesis precludes cellular prolifera- 
tion. In addition, because a number of studies have 
demonstrated that mevalonate and some of its 
metabolites are necessary for many cellular func- 
tions, ranging from cholesterol synthesis to growth 
control,40 blockade of its synthesis by HMG-CoA 
reductase inhibitors may simultaneously inhibit 
myocyte proliferation through a number of mecha- 
nisms. 
Trials w&h HMOCoA redudase inhibttors In 
preventfon of restenosk Lovastatin has been 
used in 2 clinical trials to prevent restenosis after 
coronary angioplasty, with conflicting results.43-45 
In the first tria1,43 investigators reported a reduc- 
tion in the frequency of recurrence of a diameter 
stenosis 2 50% that ranged from 45% in the 
untreated to 15% in the treated group. However, 
the study was not blinded, angiographic follow-up 
was available in only two thirds of treated and one 
third of untreated patients, and only 157 patients 
were included-thus covering each of the 3 major 
limitations of the clinical restenosis trials already 
mentioned.26 In fact, the use of a categorical 
definition of angiographic restenosis has been 
widely demonstrated as unsatisfactory and insensi- 
tive for the objective evaluation of outcome of 
so-called restenosis prevention trials.2629 Accord- 
ing to these criteria, this study must be considered 
to be fraught with weakness and the results of 
doubtful value. 
The second lovastatin trial was designed as a 
multicenter, double-blind, placebo-controlled trial 
to determine whether administration of lovastatin, 
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40 mg orally twice daily, starting 7-10 days before 
and continuing for 6 months after PTCA, would 
reduce the rate of restenosis (defined as a diameter 
stenosis >50% at follow-up angiography) after 
successful PTCA.45 The main working hypothesis 
was that by lowering serum lipids, lovastatin therapy 
might promote endothelial healing and restoration 
of normal endothelial-derived relaxation and thus 
prevent restenosis. Although significant lipid- 
lowering effects were indeed achieved by lovastatin 
compared with placebo in this trial, no prevention 
of restenosis could be demonstrated in terms of 
reduction in the frequency of recurrence of a 
diameter stenosis 250% or in the final angio- 
graphic minimal luminal diameter (MLD) at follow- 
up. Thus, it was concluded that lipid lowering does 
not prevent restenosis after successful coronary 
balloon angioplasty.45 
THE FLWASTAmN ANGlOPlASlY RESTENOSIS 
(FLARE) lRlAl. 
Deslgn, aim, and working hypothesis: Fluva- 
statin is a novel, fully synthetic HMG-CoA reduc- 
tase inhibitor that is subject to a high first-pass 
hepatic metabolism, with correspondingly low sys- 
temic bioavailability and a short plasma half-life. 
The Fluvastatin Angioplasty Restenosis (FLARE) 
Trial was conceived and inaugurated as a multi- 
center, multinational, randomized, double-blind, 
placebo-controlled trial to investigate whether 
fluvastatin, at a dosage of 40 mg twice daily for 2-4 
weeks before and continued for 26 2 2 weeks after 
successful coronary balloon angioplasty (see Appen- 
dix l), could reduce the degree of luminal renarrow- 
ing during follow-up, measured by an automated 
quantitative angiographic system (Appendix 2) as 
the deterioration in MLD from post-PTCA to 
follow-up angiography. The working hypothesis 
was that fluvastatin would reduce luminal renarrow- 
ing by a direct inhibitory effect on proliferating 
smooth muscle cells through the action described 
above, based on previous experimental findings. 
Taking account of the aggressive immediate bio- 
logic reaction to arterial injury already described, it 
was decided to incorporate a 2-week pre-PTCA 
treatment phase in the FLARE Trial to allow 
sufficient time for tissue distribution and accumula- 
tion of fluvastatin in advance of balloon angio- 
plasty. 
Fundamental deslgn and structural dlffer- 
ences between the fluvastatin and lovastatin 
restenosis trials: Although the FLARE study was 
designed while the Lovastatin Restenosis Trial was 
still in progress, the steering committee (Appendix 
3) and investigators (Appendix 4) were not de- 
terred by the neutral preliminary results of the 
lovastatin trial for a number of reasons. 
First, the primary working hypotheses of the 2 
trials are inherently different: the FLARE study 
investigates fluvastatin’s potentially beneficial di- 
rect inhibitory effect on the coronary vascular 
myocyte, independent of any influence on serum 
lipid concentrations, as stated previously, whereas 
the Lovastatin Restenosis Trial investigated aggres- 
sive lipid lowering as the putative antirestenosis 
mechanism. 
Second, in experimental studies, although all 
the HMG-CoA reductase inhibitors were found to 
inhibit myocyte proliferation, fluvastatin demon- 
strated greater inhibitory effects on neointimal 
formation than did lovastatin. 
Third, the pretreatment period in the FLARE 
Trial is 2-4 weeks before angioplasty, compared 
with 7-10 days in the lovastatin trial, to ensure 
adequate tissue distribution of fluvastatin. 
Fourth, the primary categorical endpoint cho- 
sen by the lovastatin group could be considered 
insensitive for measuring prevention of luminal 
renarrowing by a pharmacologic agent, and also 
the target reduction of 50% in the angiographic 
restenosis rate could be considered a little overam- 
bitious; thus, a type II error may have been 
inadvertently made (only 322 patients had angio- 
graphic follow-up, compared with > 500 patients in 
the CARPORT32 Trial, > 600 patients in each of 
the MERCATOR, PARK,33,35 and REDUCE tri- 
als, and > 1,200 patients in the MARCATOR34 
and HELVETICA trials). The sample size in the 
lovastatin trial, as calculated, was also reported to 
be sufficient to detect a difference of 0.36 mm in 
MLD at follow-up between the 2 groups, with 90% 
power and at an 01 level of 0.05. Such a treatment 
effect would again have to be retrospectively consid- 
ered to be an ambitious target, because even 
randomized comparison of Palmaz-Schatz coro- 
nary stent implantation with balloon angioplasty in 
520 patients demonstrated a superior MLD at 
follow-up of only 0.18 mm (favoring the stent 
group)-although this was, nevertheless, statisti- 
cally significant (p = 0.004).46 
In the FLARE Trial, the calculation of sample 
size was based on the knowledge that the mean 
luminal loss during follow-up after successful PTCA 
among placebo-treated groups in 4 previous trials 
with different agents was 0.30 mm.32-35 Thus, it was 
assumed that the placebo group in the FLARE 
Trial would demonstrate a similar degree of loss. 
With fluvastatin, the target treatment effect de- 
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TABLE I Chronological Study Schedule 
Visit (wk) 
1 2 3 415 6 
(-4to -2) (0) (6) (26 t 2) (40) 
Randomization 
Clinical 
assessment 
Concomitant 
medication 
Physical 
examination 
Lipid 
assessment 
Safety 
laboratory 
evaluations 
Fibrinogen 
Electrocardiogram 
Exercise test 
Dispensing 
Angioplasty 
Angiography (for quantitative 
coronary angiography) 
Compliance 
check 
Adverse events 
check 
X 
X 
X 
X 
X* 
X 
X 
X 
et 
X 
x x X 
x x X 
x x X 
x x X* 
x x X 
X 
x x X 
XS 
X 
X 
X X 
x x X 
x x X 
*Lipoprotein(a) and apollpoprotein Al and 6 will be measured only at visits 1 and 4. 
tExercise testinn is done at the discretion of the investigator but is not a reauirement 
of the trial. - 
*Exercise testing must be performed no more than 2 weeks before follow-up 
angiography. 
tided on was a 30% reduction in luminal loss. To 
detect such a difference with 90% power at an (Y 
level of 0.05, approximately 730 evaluable patients 
would be required. Allowing for an estimated 
dropout rate of 15% (based on experience with 
previous trials and taking account of the pretreat- 
ment phase required in the FLARE Trial), 830 
patients would need to be randomized. Such a total 
number of evaluable patients would also allow the 
detection of a difference of 30% in the incidence of 
major adverse cardiac events (death, myocardial 
infarction, coronary artery bypass graft surgery, or 
reintervention) between the treated and placebo 
groups, with a power of > 90% at an cx level of 0.05. 
Trial chronol~ The trial commences (visit 1, 
weeks -4 to -2, depending on when PTCA is 
performed; Table I) when eligible patients who 
have been screened and fulfill all inclusion and 
exclusion criteria (Table II) and have given in- 
formed consent are randomized to the control or 
treatment groups. Patients in the control group 
receive placebo twice daily and patients in the 
treatment group receive fluvastatin 40 mg twice 
daily to be taken orally for a continuous period of 
28 -+ 4 weeks (2-4 weeks before PTCA and until 
follow-up angiography at 26 ? 2 weeks). 
After a minimum of 2 weeks, the patient returns 
for PTCA, prior to which clinical and laboratory 
assessments are carried out (visit 2, week 0). Trial 
medication is continued during the hospital stay, 
the length of which is at the discretion of the 
treating physician. Patients undergoing successful 
PTCA (defined as diameter stenosis < 50%) with- 
out reaching a primary clinical endpoint continue 
on trial medication. A clinical follow-up visit is 
required 6 weeks after PTCA (visit 3, week 6). A 
further clinical assessment, with exercise testing, is 
required prior to fohow-up angiography, which is 
carried out 26 ? 2 weeks after PTCA. The clinical 
and laboratory assessments and exercise test must 
be carried out prior to angiography but may be 
done during the same visit or on a separate day, 
according to the preference of the treating physi- 
cian and individual patient (visits 4 and 5, weeks 
24-28). The investigators decided that final clinical 
follow-up for evaluation of clinical endpoints would 
occur 40 weeks after PTCA (visit 6, week 40) to 
allow sufficient time for performance of justified 
(on the basis of recurrent symptoms or demon- 
strated exercise-induced ischemia) elective reinter- 
vention or bypass graft surgery as determined by 
clinical and angiographic follow-up at 26 & 2 weeks. 
Because of variable waiting time for elective surgi- 
cal or nonsurgical intervention throughout the 
participating countries, it was decided that 40 
weeks was the most practical time for final clinical 
follow-up. 
Pdmaty angkgraphk endpdnt: The primary 
endpoint for the FLARE Trial is the change in 
MLD, in millimeters, between the post-PTCA and 
the follow-up angiogram, 26 2 2 weeks after the 
PTCA procedure, measured by quantitative coro- 
nary angiography. If, for whatever reason, angiogra- 
phy is carried out prior to 14 weeks after PTCA, 
further angiography within the recommended time 
window will be required, unless a primary clinical 
endpoint, as defined below, has been reached. 
Secondary angiographic objectives: The sec- 
ondary objectives are: (1) minimal luminal diam- 
eter at follow-up angiography; and (2) the relation 
between acute luminal gain and late luminal loss 
for the treatment and control groups, taking all 
other potentially confounding parameters into con- 
sideration, using multiple linear regression analysis 
techniques to investigate whether treatment with 
fluvastatin beneficially alters, or modifies, the heal- 
ing response of the vessel wall to the injury im- 
parted at PTCA. 
Tertiary anglographk obJective: Incidence of 
restenosis is defined according to a selection of 
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categorical angiographic criteria (see definitions in 
Appendix 1). 
Primary clinkal endpoInts A primary clinical 
endpoint will be considered to have been reached 
on the occurrence of any 1 of the major adverse 
cardiac events described later, before 40 weeks 
postsuccessful PTCA. At the outcome of the trial, 
the primary clinical endpoints will be described in 
terms of the incidence of the following events; for 
any patient experiencing > 1 event, the first event 
reached will be considered. 
1. Death: Postmortem examination is recom- 
mended in all randomized patients who die during 
the course of the trial. If there is no clear evidence 
to the contrary, any deaths occurring during the 
trial will be considered to be cardiac. 
2. Nonfatal myocardial infarction: The occur- 
rence of myocardial infarction will be defined as 
the finding of a typical temporal pattern of serum 
cardiac enzyme change; in particular, documented 
elevation of serum creatine kinase levels to greater 
than twice the upper limit of normal for the 
laboratory and/or a >Zfold increase in the cre- 
atine kinase-MB fraction, with return to within the 
accepted normal range. If there are no unambigu- 
ous cardiac enzyme abnormalities, the finding of 
typical evolutional electrocardiogram patterns of 
myocardial infarction or of “new” pathologic Q 
waves will be considered diagnostic of myocardial 
infarction. Evidence to support diagnosis of myocar- 
dial infarction must be provided by the investigator 
to facilitate final adjudication by the critical events 
and safety and data monitoring committees. 
3. The need for coronary artery bypass graft 
surgery or for stent implantation (which is consid- 
ered equivalent to the need for coronary artery 
bypass graft surgery). 
4. Need for reintervention after completion of 
the initial PTCA procedure and before the end of 
the trial period, including requirement for repeat 
PTCA or intervention using an alternative percuta- 
neous revascularization device. (Use of perfusion 
balloon catheter at the discretion of the treating 
physician is acceptable and does not constitute an 
endpoint or exclusion from the trial.) 
Secondary and tertiary cllnlcal objectives: 
All clinical events occurring during the 40-week 
trial will be recorded, for the purpose of reporting 
both a ranked classification, as a secondary clinical 
objective, and a total event count (whereby mul- 
tiple entries per patient are allowed) as a tertiary 
clinical objective of the trial. (Decisions made 
within the 40-week trial period to carry out further 
TABLE II Patients-Inclusion and Exclusion Criteria in the 
FLARE Trial 
inclusion criteria 
Men and women (who are not potentially childbearing) with native 
primary coronary artery disease amenable to PTCA. Patients with 
previous intervention of CABG surgery are acceptable if the target 
lesion is a native primary lesion only 
Clinical status stable enough to allow at least 2 weeks treatment prior to 
PTCA 
Patients must be suitable for CABG surgery, if required 
Patients must be agreeable to follow-up angiography 26 f 2 weeks 
following PTCA 
Patients must give informed consent 
Exclusion criteria 
Genera/ criteria: 
Lack of informed consent (for whatever reason) 
Females of chlldbearing age (i.e., only women who are at least 2 years 
postmenopausal or who have been surgically sterilized for at least 1 
year may be Included; premenopausal women using contraceptive 
methods are ineligible) 
Participation in another study of any investigational agent within the past 
30 days or previous participation in this study 
Malignant or other disease where life expectancy is < 1 year 
Major surgery wlthin previous 3 months 
Impaired intellectual or cognitive function likely to prevent clear 
understanding of the trial purpose and requirements or to compromise 
compliance with trial procedures 
History of drug, alcohol, or other substance abuse, making complete 
compliance with the requirements of the FLARE Trial unlikely 
Specific exclusion criteria related to performance of PTCA or coronary 
angiography: 
Allergy to contrast media 
Allergy to or intolerance of aspirin 
Target lesion in an unprotected left main coronary artery 
Target lesion m a bypass graft (arterial or venous) 
Previous intervention of the intended target lesion 
Target lesion a totally occluded vessel of >3 months’ duration 
Excessively tortuous or diseased peripheral arteries or complex peripheral 
arterial anatomy making PTCA or follow-up angiography difficult or 
dangerous 
Known or suspected bleeding diathesis 
Severe renal dysfunction (serum creatinine >20 mg/liter [180 
pmol/literl or urea > 1,200 mg/liter) 
History of a cerebrovascular accident or thromboembolic event within the 
previous 6 months 
Presence of > 1 severe lesion requiring intervention 
Intention to use any interventional device other than conventional balloon 
angioplasty 
Uncontrolled systemic hypertension (diastolic blood pressure > 100 mm 
Hgor systolic blood pressure > 180 mm Hg, despite medical therapy) 
Poor left ventricular function with an ejection fraction < 30% 
Exclusion criteria related to lipids, lipid metabolism, and the use of 
fluvastatin 
Known hypercholesterolemia or hypertriglyceridemia or detection of 
fasting low density lipoprotein cholesterol > 6.0 mmol/liter or 
triglycerides > 4.5 mmol/liter, according to the local laboratory, within 
4 weeks prior to randomization 
Evidence or history of medical condition that might place the patient at 
risk or obscure the evaluation of the safety, tolerability, or efficacy of 
fluvastatin (e.g., autoimmune diseases, nephrotic syndrome, multiple 
myeloma, dysglobulinemia or macroglobulinemia, glycogen storage 
disease, chronic pancreatitis, and porphyria) 
Use of any lipid-lowering agent (including fish oils or nonprescription 
medication that is known to affect serum lipids) within the previous 4 
weeks or exposure to probucol withm the previous 12 months 
Myocardial infarction in the previous 3 months associated with a rise in 
creatme kinase to more than twice the upper limit of normal for the 
local laboratory 
Known preexisting gallbladder disease, liver disease, or abnormal liver 
function (aspartate or alanine aminotransferase or serum bllirubin, 
>20% above the upper limit of normal for the local laboratory, within 
4 weeks of randomization) 
Chronic muscular disorder, wasting disease, or dystrophy 
Non-insulin-dependent diabetes (a potential interaction between 
fluvastatin and sulfonylureas has not been completely ruled out) 
CABG = coronary artery bypass graft; PTCA = percutaneous transluminal coronary 
anglography. 
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intervention after this time will not be included as 
clinical endpoints.) 
Lipid and laboratory aspects: Patients with 
hyperlipidemia or those with a measured fasting 
low density lipoprotein cholesterol > 6.0 mmol/ 
liter or fasting triglyceride level >4.5 mmol/liter 
(by local laboratory) within 4 weeks of randomiza- 
tion are excluded from the trial on the ethical 
principle that they require lipid-lowering therapy. 
Prior to randomization, all patients must have 
documented evidence of fasting lipid levels below 
these limits within the previous 4 weeks. 
The effect of trial medication on serum lipid 
levels will be assessed by performance of a compre- 
hensive lipid profile [total cholesterol, low density 
and high density lipoprotein cholesterol, lipopro- 
tein(a), apolipoproteins Al and B, and triglycer- 
ides] at randomization and prior to angiographic 
follow-up at 26 +- 2 weeks after PTCA. Cholesterol 
and triglycerides will also be measured pre-PTCA 
(2-4 weeks after commencement of trial medica- 
tion) and 6 weeks after PTCA. Lipid parameters 
and temporal changes therein will be compared 
between the 2 groups and correlated with the 
angiographic and clinical endpoints. 
In addition to acceptable serum lipid levels, all 
patients must have documented hematologic, he- 
patic, and renal indices and creatine kinase levels 
within the acceptable range (Table II) according to 
local laboratory limits prior to randomization. 
At randomization, blood samples will be taken 
for measurement of these parameters at a central 
laboratory. Similar laboratory tests will be re- 
peated at each patient visit to detect any potential 
adverse biochemical or hematologic effects of trial 
medication. In the final analysis, the treatment and 
placebo groups will be compared for frequency and 
severity of abnormalities detected. 
From randomization, all blood samples will be 
specially packaged in protective containers and 
sent by courier to central laboratories for blinded 
analysis. Local laboratory results will be used for 
screening and establishment of patient suitability 
for inclusion as well as for diagnosis of acute 
adverse events (all data pertaining to such events 
will be blindly evaluated by the critical events 
committee and by the safety and data monitoring 
committee, who will be unblinded). Central labora- 
tory results will be used to monitor the safety of 
trial medication, and relevant laboratory abnormali- 
ties will be reported to responsible investigators 
and the data coordinating center. 
Trial medication: 
COMPLIANCE, SAFETY, AND TOLERABILITY: In 
addition to laboratory tests, compliance with trial 
medication will be assessed at each patient visit, 
and all adverse experiences (any deterioration in 
clinical status during the course of the trial is 
considered an adverse experience; its relation with 
trial medication is determined according to well- 
known guidelines) will be documented in the case 
record form. 
DISCONTINUATION OF TRIAL MEDICATION: The 
trial medication is discontinued if: (1) PTCA is 
abandoned without the performance of balloon 
dilation or if PTCA is not performed, for whatever 
reason; (2) PTCA is unsuccessful (diameter steno- 
sis >50% post-PTCA) whether or not a major 
adverse event occurs; (3) a primary clinical end- 
point is reached or if a major adverse event (as 
defined in Appendix 1) occurs; (4) a protocol 
violation occurs. Discontinuation of trial medica- 
tion does not imply withdrawal from the trial, and 
follow-up clinical observations must be made as 
scheduled to complete the safety and intention-to- 
treat evaluation and analysis. 
CONCOMITANT MEDICATION: Other medications 
included: (1) All patients will receive acetylsalicylic 
acid up to 325 mg once daily throughout the trial 
period; (2) each set of angiographic recordings 
must be preceded by an intracoronary injection of 
l-3 mg isosorbide dinitrate or 0.1-0.3 mg glyceryl 
trinitrate to control vasomotor tone. Oral or sublin- 
gual nitrates may be given during the follow-up 
period when indicated; (3) calcium antagonists 
may be given at the discretion of the treating 
physician, during the PTCA procedure or during 
the in-hospital period; (4) antiplatelet agents and 
oral anticoagulants should not be used during the 
trial period. 
EXCLUDED MEDICATION: Excluded medications 
that may interfere with evaluation or interpreta- 
tion of study results include all lipid-lowering 
agents, steroid hormones or oral contraceptive 
agents, thyroid hormone replacement (acceptable 
only if the patient is euthyroid and the dose being 
taken has not changed in the previous 2 months 
and is also unlikely to change during the trial; 
otherwise, the patient is excluded), erythromycin, 
ketoconazole, cyclosporine, and antiepileptic 
therapy. 
STATISTICAL PLAN: The calculation of patient 
numbers required for appropriate evaluation of 
the trial outcome has already been described. 
EVALUATION OF SAFETY: All patients random- 
ized and receiving at least 1 dose of trial medica- 
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tion will be included in an evaluation of the safety 
of trial medication (Table III). 
INTENTION-TO-TREATANALYSIS: Theprimarypa- 
rameter for the confirmatory analysis is the angio- 
graphically determined change in MLD from the 
post-PTCA to the follow-up angiogram, using the 
intention-to-treat population (shown in Table II). 
The control and treatment groups will also be 
compared with respect to baseline clinical and 
angiographic parameters and angioplasty proce- 
dural data, the occurrence of primary clinical 
endpoints up to week 40 following angioplasty, and 
the secondary and tertiary clinical and angio- 
graphic endpoints or objectives, compliance with 
and tolerability of trial medication, use of concomi- 
tant medication, incidence of adverse events, lipid 
and biochemical parameters, clinical status at fol- 
low-up, and exercise test results prior to follow-up 
angiography. Continuous variables, especially the 
change in MLD during and at follow-up, will be 
compared by analysis-of-variance techniques, tak- 
ing potential center (investigating institution) inter- 
action into account. Categorical variables will be 
compared by Mantel-Haenszel test procedures. 
Incidence of clinical endpoints, adverse events, 
and patient dropout from the trial after randomiza- 
tion will be compared using contingency method 
tables (i.e., chi-square statistics). Binary restenosis 
rates (according to the conventional definitions 
employed) will be compared by Fisher’s exact test. 
Multiple logistic and linear regression analysis 
techniques will be used to relate primary angio- 
graphic outcome (change in MLD during follow- 
up) to primary clinical outcome (incidence of 
major adverse cardiac events, where only the first 
event experienced is counted for each patient) and 
to lipid outcome (change in lipid parameters dur- 
ing follow-up), taking all other potentially con- 
founding factors into consideration (for example, 
luminal gain, MLD pre-PTCA, reference vessel 
diameter, lesion location, and duration of preexis- 
tent angina). In this manner, independent determi- 
nants of angiographic, clinical, and lipid outcome 
may also be investigated. 
PER PROTOCOL ANALYSIS: A per prOtOCOl Nldy- 
sis will also be performed on patients as character- 
ized in Table II. All assessments in the intention-to- 
treat analysis will also be evaluated by the per 
protocol analysis. 
SUMMARY 
The rationale for use of fluvastatin in the 
FLARE Trial is thus based on good experimental 
evidence that suggests potential treatment benefit 
TABLE III Statistical Plan 
Patients Parameter of Analysis 
All randomized patients who Clinical events (safety analysis) 
received at least 1 dose of trial 
medication, whether or not PTCA 
was performed 
All randomized patients who 
received at least 1 dose of 
treatment and underwent 
successful PTCA 
Clinical events 
Angiographic endpoints 
(intention-to-treat analysis) 
Patients treated per protocol, i.e., all 
randomized patients who: 
Underwent successful PTCA as Clmical events 
defined in the protocol Angiographic endpoints (per 
protocol analysis) 
Completed the treatment course 
according to the protocol (28 
weeks f 15% missed medication 
is acceptable) 
Underwent angiography and 
clinical follow-up according to the 
protocol 
in reducing neointimal proliferation after success- 
ful angioplasty by direct inhibition of myocyte 
proliferation. The 2 central design features of the 
FLARE study are: (1) it is a prospective, random- 
ized, double-blind, placebo-controlled trial with an 
objective primary angiographic endpoint, namely, 
the change in MLD from post-PTCA to follow-up 
angiography, measured by a computer-assisted, 
automated edge detection system in a central, 
independent, core laboratory; and (2) a pre-PTCA 
treatment phase of 2-4 weeks will allow adequate 
accumulation of fluvastatin in tissue before vessel 
injury occurs at PTCA. In addition, this trial 
provides an opportunity to compare prospectively 
and evaluate the relation of various lipid param- 
eters and changes therein, as a consequence of 
therapy with fluvastatin, to the development of 
luminal renarrowing (and major adverse cardiac 
events) after successful PTCA in a large patient 
group. 
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APPENDIX 1 
Definitions: 
COMPLIANCE: Compliance with trial medication 
is based on the pill count at each patient visit and 
will be considered unsatisfactory at 8 weeks (visit 
3) if <90% of appropriate trial medication has 
been taken or if trial medication has been omitted 
for 3 consecutive days. At follow-up angiography 
(visit 5) if <80% of trial medication has been 
taken or if it has been omitted for > 3 consecutive 
days. If a patient misses a scheduled visit by > 1 
week, noncompliance is also defined. 
SUCCESSFUL PERCUTANEOUS TRANSLUMINAL 
CORONARY ANGIOPLASTY: Successful PTCAis de- 
fined as residual diameter stenosis after balloon 
angioplasty < 50% visually assessed by the interven- 
tionalist without the use of an adjunctive interven- 
tional device and without the occurrence of a major 
adverse cardiac event (also described in the text). 
PRIMARY CLINICAL ENDPOINT: Described in the 
text. 
MAJOR ADVERSE CARDIAC EVENT: Defined as 
the occurrence of death, myocardial infarction (as 
defined in the text), or need for coronary artery 
bypass graft surgery or reintervention at any time 
after randomization but within 40 weeks of angio- 
plasty. 
PRIMARY ANGIOGRAPHIC ENDPOINT: Described 
in the text. 
FOLLOW-UP ANGIOGRAM: The follow-up angio- 
gram is defined as angiography carried out at the 
optimum time of 26 + 2 weeks after PTCA and 
must be performed according to the instructions of 
the angiographic core laboratory as provided in the 
technician’s work sheet. 
INTERCURRENTANGIOGRAPHY: Angiographycar- 
ried out before 14 weeks post-PTCA is acceptable 
as the follow-up angiogram if the target vessel is 
now occluded or if significant renarrowing has 
occurred requiring reintervention or bypass graft 
surgery. Otherwise, further angiography within the 
recommended time window will be required. For 
good clinical indications, angiography after 14 
weeks is acceptable as the follow-up angiogram. 
RESTENOSIS: In this trial, restenosis is defined as 
the loss in MLD from post-PTCA to follow-up 
angiography. However, as already mentioned in 
the text, conventional categorical angiographic defi- 
nitions of restenosis will be applied to the collected 
patient data and evaluated accordingly. These 
definitions include: (1) A diameter stenosis > 50% 
at follow-up angiography (2) National Heart, Lung, 
and Blood Institute definition IV, i.e., loss during 
follow-up 250% of the initial gain achieved at 
PTCA; (3) loss of 20.40 mm in MLD during 
follow-up, which represents twice the post-PTCA 
lesion measurement variability for the cardiovascu- 
lar angiographic analysis system quantitative coro- 
nary angiography system47 under current standard- 
ized angiographic acquisition and analytical 
conditions. 
APPENDIX 2 
Quantitative coronary angiographk method- 
ology: 
STANDARDIZATION OF ANGIOGRAPHIC ACQUISI- 
TION PROCEDURES BY INVESTIGATORS TO FACILI- 
TATE QUANTITATIVE ANALYSIS: The following pro- 
cedures have been standardized: 
1. 
2. 
3. 
4. 
5. 
6. 
Intracoronary nitrate before angiography pre- 
PTCA, post-PTCA, and at follow-up 
Use of nonionic contrast, prewarmed to 37” C 
Contrast-empty catheter (at least 6F) filmed 
before each injection plus distal 20 cm sent with 
film for micrometric measurement by core labo- 
ratory 
Optimal arterial opacification for at least 3 
cardiac cycles 
Avoidance of bony structures or closely parallel/ 
overlapping branches 
At least 2 projections 260’ apart for right 
coronary artery lesions and at least 3 projections 
2 30” apart for left coronary artery lesions 
Identical projection angulations and table height, 
pre-PTCA, post-PTCA, and at follow-up 
Radiopaque indicators filmed to identify bal- 
loon inflation pressures and administration of 
intracoronary nitrate 
Guide wire and balloon catheter removed be- 
fore final post-PTCA angiogram 
CORE-LABORATORY STANDARDIZATION PROCE- 
DURES FOR QUANTITATIVE ANALYSIS: Procedures 
standardized for quantitative analysis are: 
1. Automated edge detection using the cardiovas- 
cular angiographic analysis system 
2. Micrometrically measured catheter tip used as 
scaling device 
3. Panel evaluation of projections and frames se- 
lected by investigator 
4. Analysis of optimal end-diastolic frames in least 
foreshortened projections 
5. Automatic corrections for pincushion distortion 
of image intensifier 
6. Comprehensive range of measurements pro- 
vided for each segment analyzed 
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1. 
7. Polaroid print of each analysis to confirm match- 
ing of projections pre-PTCA, post-PTCA, and 
at follow-up 
8. Careful evaluation and error check before each 
analysis is verified and entered on database 
9. Final measurements used are the means of the 
multiple matched projections 
CARDIOVASCULARANGIOGRAPHICANALYSISSYS- 
TEM: The procedural and technical details of this 
system are beyond the scope of this article and 
have been described in detail elsewhere.18,24 In 
summary: 
2. 
3. 
4. 
5, 
6. 
7. 
8. 
An area measuring 6.9 x 6.9 mm (512 x 512 
pixels) from the selected cineframe (18 x 24 
mm), encompassing the arterial segment of 
interest, is digitized with a high-resolution charge 
coupling device camera 
The segment of interest is analyzed between 
nearest proximal and distal side branches 
Center points within the arterial segment are 
selected by the analyst (the accuracy of this 
process is unimportant, because the computer 
subsequently automatically readjusts the center 
line after contour detection) 
Vessel contours are detected automatically, 
based on the weighted sum of first and second 
derivative functions, applied to the digitized 
brightness information, along scan lines perpen- 
dicular to the local center line directions of the 
arterial segment 
An interpolated reference diameter is derived 
automatically. For this purpose, the lesion itself 
is excluded, using the curvature analysis (which 
identifies the proximal and distal ends of the 
lesion); then, in a continuous fashion, the arte- 
rial contours over the lesion are interpolated on 
the basis of the proximal and distal center line 
segments and a first-degree polynomial through 
all the diameter values, followed by a transla- 
tion to the 80th percentile level, taking physi- 
ologic tapering of the vessel (beyond side 
branches) into account 
Calculation of absolute dimensional measure- 
ments requires use of the contrast-free catheter 
tip as the scaling device48 
The length of the lesion is determined from the 
diameter function on the basis of curvature 
analysis that identifies the proximal and distal 
extremities of the actual narrowed segment 
Because the algorithm cannot measure total 
occlusions or lesions with Thrombolysis in Myo- 
cardial Infarction Study Group (TIMI) flow 
grade I, a value of 0 mm is substituted for the 
MLD and 100% for the percent diameter steno- 
sis in these circumstances, and the interpolated 
reference diameter post-PTCA is used as the 
reference diameter pre-PTCA 
APPENDIX 3 
Trlalorgan&ationalbalea: 
STEERING COMMITTEE: A steering committee has been 
formed, consisting of: Prof. Patrick W. Serruys, Thorax- 
center, Erasmus University, Rotterdam, The Netherlands; 
the principal investigators from each of the 4 participating 
European countries; directors of each of the angiographic 
core laboratories, the clinical coordinating center, and the 
lipid core laboratory; chairpersons of each of the other 
committees; and representatives of the sponsor (Sandoz 
Pharma, Basel, Switzerland). The steering committee is the 
main policy and decision-making committee of the study 
and has final responsibility for the scientific conduct. 
SPONSOR: Sandoz Pharma: Dr. P. J. Pfister, Corporate 
Management, Basel, Switzerland; Dr. A. DeBlander, Brus- 
sels, Belgium; Mr. M. T. Rudolphie, Uden, The Nether- 
lands; Dr. I. Porta Pujol, Barcelona, Spain; Dr. J. Jewitt- 
Harris, Surrey, United Kingdom. 
ANGIOGRAPHIC CORE LABORATORY: The angiographic 
core laboratory is at Cardialysis, Rotterdam, The Nether- 
lands. The tasks of the core laboratory include: (1) working 
with investigators in setting up local procedures for angiog- 
raphy suitable for quantitative analysis; (2) performing 
quantitative analysis of study angiograms provided by 
investigators; (3) preparing, updating, and maintaining the 
angiographic computer database; and (4) liaising with the 
angiographic committee of the FLARE Trial to ensure 
provision of reliable angiographic data to the satisfaction of 
all participants in the trial. 
DATA COORDINATING CENTER: The data coordinating 
center is located at Sandoz Pharmaceuticals, Surrey, United 
Kingdom, and is responsible for: (1) working with local 
investigators and study monitors to ensure accuracy and 
reliability of clinical data and punctual and efficient trans- 
fer of case record forms and clinical information from 
investigators; (2) preparing, updating, and maintaining the 
clinical database; and (3) liaising with the angiographic 
core laboratory, including regular transfer of data as 
required from time to time, to ensure provision of reliable 
clinical data to the satisfaction of all participants in the 
trial. 
Each of the following committees has a chairperson who 
will be responsible for the committee performing its function in 
an eficient manner throughout the trialperiod. 
ADVISORY AND DATAMONITORING COMMITTEE:?% is 
an independent committee consisting of 4 acknowledged 
experts (Prof. P. G. Hugenholz, Mies, Switzerland; Prof. B. 
Meier, Geneva, Switzerland; Prof. D. W. Erkelens, Utrecht, 
Netherlands; Prof. L. Wilhelmsen, Goteborg, Sweden) in 
the relevant disciplines of interventional cardiology, lipidol- 
ogy, and epidemiology who are not otherwise associated 
with the trial and who will act in a senior advisory capacity 
on matters of safety of trial procedures and in evaluating 
the reliability of the data collected. This committee will also 
ensure that the study is performed in accordance with the 
Declaration of Helsinki. This committee periodically re- 
views, unblinded, treatment-monitoring reports for evi- 
dence of unexpected adverse or beneficial effect of trial 
medication. The committee is entitled to recommend 
6OD THE AMERICAN JOURNAL OF CARDIOLOGY VOLUME 73 MAY 26, 1994 
amendments of the protocol or early termination of the trial 
to the steering committee. 
CRITICALEVENTS COMMITTEE: Acritical eventscommit- 
tee consisting of 3 experienced investigators will blindly 
review clinical data to identify the occurrence of any major 
adverse cardiac events. 
ANGIOGRAPHY COMMITTEE: The angiography commit- 
tee, consisting of 3 members, will approve the procedures 
and evaluations applied and carried out by the angiographic 
core laboratory for quantitative analysis. Guidelines for 
interpretation of the angiograms and for quantitative analy- 
sis will be further elaborated by this committee, which will 
work in close collaboration with the angiographic core 
laboratory and provide arbitration of any angiographic 
difficulties and dilemmas arising during the trial. 
PUBLICATIONS COMMITTEE: A publications committee 
consisting of the investigators will evaluate and report the 
results of the study, with the cooperation and permission of 
the sponsor. 
APPENDIX 4 
l&t ofimf66tigator6: 
BELGIUM: Dr. G. Heyndrickx, Onze Lieve Vrouw- 
ziekenhuis, Aalst; Dr. M. Vrolix, Algemeen Ziekenhuis 
Sint Jan, Genk; Dr. V. Legrand, CHU Sart Tilman, Liege; 
Dr. W. Wijns, U.C.L. Saint-Luc, Brussels; Dr. P. Materne, 
Hbpital de la Citadelle, Liege; Dr. Y. Taeymans, R.U., 
Gent. 
THE NETHERLANDS: Dr. J. J. R. M. Bonnier, Catharina 
Ziekenhuis, EJ Eindhoven; Dr. A. van Boven, Academisch 
Ziekenhuis Groningen, Groningen; Dr. P. J. de Feyter, 
Academisch Ziekenhuis Dijkzigt, Rotterdam; Dr. G. J. 
Laarman, Onze Lieve Vrouwe Gasthuis, Amsterdam; Dr. 
H. Suryapranata, Ziekenhuis De Weezenlanden, Zwolle. 
IRELAND: Dr. P. Crean, St. James Hospital, Dublin. 
UNITED KINGDOM: Dr. P. Bloomfield, Royal Infirmary of 
Edinburgh, Edinburgh, Scotland; Dr. C. Handler, North- 
wick Park Hospital, Harrow, Middlesex, England; Dr. D. 
Dymond, St. Bartholomew’s Hospital, London, England; 
Dr. 1. Hutton, Royal Infirmary, Glasgow, Scotland; Dr. R. 
Foale, St. Mary’s Hospital, London, England; Dr. C. Ilsley, 
Harefield Hospital, Harefield, Middlesex, England; Dr. 
A.H. Gershlick, Glenfield Hospital, Leicester, England; Dr. 
G. Jackson, Guys Hospital, London, England; Dr. R. Hall, 
University Hospital of Wales, Cardiff, Wales; Dr. D. Lipkin, 
The Royal Free Hospital, London, England; Dr. J. Rams- 
dale, Cardiothoracic Centre, Liverpool, England; Dr. M. 
Rothmann, The London Hospital, London, England; Dr. L. 
Shapiro, Papworth Hospital, Cambridge, England; Dr. A. 
Timmis, London Chest Hospital, London, England. 
SPAIN: Dr. J. Escaned, Sanatorio Quirurgico Modelo, 
La Coruria; Dr. J. L. Delcan Dominguez, Hospital General 
Gregorio Maranon, Madrid; Dr. C. Macaya, Hospital 
Universitario San Carlos, Madrid; Dr. A. Betriu, Hospital 
Clinic i Provincial, Barcelona 
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